Apyx Medical Q2 Revenue Climbs 22% to $13.9M, Full-Year Guidance Reaffirmed
APYX has more than doubled off its 52-week low of $1.7.
Summary
Apyx Medical reported Q2 2026 revenue of $13.9 million, a 22% increase year-over-year, and reaffirmed its full-year revenue guidance. The net loss narrowed, but cash reserves declined, and a new patent lawsuit was disclosed.
Key Events · Earnings and Guidance · APYX
-
Q2 Revenue Up 22%
Revenue reached $13.9 million, driven by a 28.1% surge in the Surgical Aesthetics segment to $12.4 million, fueled by AYON system sales and higher handpiece volumes.
-
Net Loss Narrows
Net loss attributable to stockholders was $3.2 million ($0.07 per share), compared to $3.8 million ($0.09 per share) in Q2 2025, reflecting improved operating leverage.
-
Full-Year Guidance Reaffirmed
Management reiterated its full-year 2026 revenue guidance, signaling confidence in the commercial trajectory despite ongoing losses.
-
Cash Burn Continues
Cash and cash equivalents fell to $27.6 million from $31.7 million at year-end 2025. The company states it may need additional equity or debt financing, which could dilute shareholders.
Analysis · APYX · Industrial Applications And Services
A solid second quarter saw Apyx Medical post 22% revenue growth, propelled by its Surgical Aesthetics segment and the AYON Body Contouring System. The net loss narrowed to $3.2M from $3.8M a year ago, and management reaffirmed its full-year revenue outlook. Still, cash burn remains a concern — reserves slipped to $27.6M from $31.7M at year-end, and the company acknowledges it may need additional financing. A new patent infringement lawsuit filed in July adds litigation risk. The results demonstrate commercial momentum but also underscore the delicate balance between growth and liquidity.
At the time of this filing, APYX was trading at $3.88 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $174.4M. The 52-week trading range was $1.70 to $5.08. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.